NCT01872078 - A Study of AZD4901 in Females With Polycystic Ovary Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

Interventions

DRUG

AZD4901 (oral)

Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo

DRUG

Placebo to match AZD4901

Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo

Trial Locations (7)

Miami Research Associates, Miami

Research Site, Orlando

Research Site, Springfield

Research Site, Berlin

Research Site, Belfast

Research Site, Edinburgh

Research Site, London